A recent single-arm phase II trial explored the efficacy of adding LAT to the treatment of residual disease in patients with EGFR-mutated NSCLC who achieved oligo-residual disease after 3 months of EGFR-TKI treatment. Here, EGFR is linked to non-small cell lung carcinoma.